BioLargo Protects its Intellectual Property, Revokes Pooph License Due to Failure to Pay and Other Contract Breaches

Stock Information for Inhibikase Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inhibikase Therapeutics Inc.

BioLargo Subsidiary BEST Featured in Chemical Engineering Magazine for PFAS Breakthrough
BioLargo to Present at NobleCon's 21st Annual Emerging Growth Equity Conference, Dec. 2-3, 2025
BioLargo Reports Q3 2025 Operating and Financial Results
BioLargo Q3 2025 Earnings Results Webcast and Conference Call on Friday, November 14th, 2025 - 4:30 PM Eastern Time
BioLargo Subsidiary Clyra Medical Technologies Forms Strategic Alliance with Advanced Solution to Launch ViaCLYR(TM) Wound Irrigation Solution Nationwide
BioLargo Files Federal Lawsuit Against Pooph Inc.
BioLargo Cuts AEC PFAS Treatment Energy Use by >90%, Unlocking Commercial-Scale Water Solutions with Unmatched Total Life Cycle Cost Savings
BioLargo Presentation Deck at LD Micro Event Available Online

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.